81 In the index

NSI-189 NSI

An experimental compound tested in human trials for major depression, based on how it affected brain-cell growth in animals. The depression trials in people didn't clearly show it worked better than placebo, and development hasn't moved forward.

Also known as NSI-189 phosphate, YVE9U408ZL, RefChem:854938, Amdiglurax, amdiglurax [INN], orb1226632, orb1307355, EX-A277, CHEBI:228696

Effects Focus Mood

Routes Oral

Legal status Research chemical

WADA Not listed

3D Molecular Structure of C₂₂H₃₀N₄O

Drag to rotate · scroll to zoom

Chemistry

Formula: C22H30N4O
Molar mass: 366.5
CAS: 1270138-40-3
PubChem CID: 50922681
IUPAC name: (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)-3-pyridinyl]methanone
InChIKey: DYTOQURYRYYNOR-UHFFFAOYSA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established for humans

Reported range Phase I/II trial doses: 40-80 mg/day (studied for depression, development discontinued)

Route Oral

Frequency Once daily (trial protocol)

Duration Trial duration of 6 weeks

An experimental hippocampal-neurogenesis compound whose depression trial did not show sufficient benefit; development was discontinued, and it was never approved. Now sold only as an unregulated research chemical.

Where this comes from Published Phase I/II clinical trial data; user-reported/research-chemical vendor literature

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.